18results about "Enkephalins" patented technology

Provided herein are antibodies and antigen binding fragments thereof specific to BCG antigen Ag85B as well as chimeric antigen receptors and lymphocytes comprising Ag85B antibodies as described and methods of treating cancer and tuberculosis infections using the CAR lymphocytes described. In a first aspect, provided herein is an isolated antibody or antigen binding fragment thereof capable of binding Bacillus Calmette-Guerin (BCG) antigen Ag85B.

The disclosure provides Tn epitope-specific chimeric antigen receptors and scFvs, including soluble scFvs and multimeric scFvs, as well as methods of identifying cancer subjects and cancer subject sub-populations amenable to anti-Tn immunotherapy and methods of treating cancer.

The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

Provided herein are methods of using modified caveolin-1 (Cav-1) peptides to treat or prevent a kidney disease or disorder in a subject. In particular, provided are methods of using the modified Cav-1 peptides for the treatment of chronic kidney disease characterized by fibrosis, such as, for example, Alport syndrome.

The present invention provides delivery vectors for transferring a nucleic acid sequence to a cell in vitro, ex vivo or in vivo. The present invention provides methods of delivering a nucleic acid sequence to a cell and methods of treating focal epilepsies.

Artificial expression constructs for the rescue of voltage-gated sodium channel function using intein-mediated reconstitution of the SCN1A encoded protein, voltage-gated sodium channel alpha subunit 1 (Nav1.1) are described. Rescued voltage-gated sodium channel function can be used to treat disorders such as epilepsy, and more particularly, Dravet Syndrome.

Embodiments of the disclosure include methods and compositions for producing T cell receptor (TCR) polypeptides specific for hematological neoantigens. In specific embodiments, T cells directed to one or more hematological neoantigens are produced following exposure of PBMCs to peptides that encompass one or more neoantigens, and the TCRs in the produced T cells are tested for efficacy and identified. The neoantigen-specific TCRs are utilized in a variety of immunotherapies.

Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of angiotensinogen (AGT); pharmaceutical compositions including the same, and methods of treatment using the same.

The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising a first chimeric antigen receptor (CAR) capable of binding human IL13Rα2, a second CAR capable of binding EGFR or an isoform thereof, and a dominant negative TGFbβ type II receptor (DN-TGFbβRII). Compositions and methods of treatment are also provided.

The present disclosure provides a modified immune cell or a precursor thereof (e.g., a T cell) comprising a first chimeric antigen receptor (CAR) capable of binding to human IL13R [alpha] 2, a second CAR capable of binding to EGFR or an isoform thereof, and a dominant negative TGFRII receptor (DN-TGFRII). Compositions and methods of treatment are also provided.

The invention relates to the field of active peptide preparation, in particular to a preparation method and application of modified protein peptide for improving memory, and the preparation method comprises the following steps: S1, adding modified chimeric peptide and piperine into 70% wt of ethanol aqueous solution, and adding zein to obtain an organic phase; according to the invention, a neuroprotective peptide fragment and a core memory improving peptide are embedded by an enzyme method and subjected to fixed-point palmitoylation modification, and then the neuroprotective peptide fragment and the core memory improving peptide are entrapped in zein-chitosan nanoparticles together with an absorption enhancer piperine, so that an oral co-loading delivery system is constructed; functional synergy and efficient targeted delivery of the active peptide are achieved, meanwhile, the whole preparation process is green and mild, purification is efficient, the bioavailability, efficacy and production feasibility of polypeptide products are remarkably improved, and the polypeptide has wide application prospects in the fields of functional food, special medical food and pharmaceutical preparations.

Present invention discloses a new method for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR) that provides several improvements over conventional manufacturing methods, thereby enabling production of a robust supply of clinically useful CAR T-cell therapies with higher percentage of CAR positive cells with improved naive and memory cells in a short timeframe and in a cost-effective manner. Further similar method can be used to manufacture NK-CAR, TIL and other immune effector cells useful for immunotherapy. This new method treats the patient / human body as a bioreactor wherein the CAR-T cells expand on encountering the target antigen in their natural environment thus making them more efficient in terms of persistence and efficacy in neutralizing the tumours.

The invention provides a. genetically modified non-human animal that comprises in its genome foreign γ and δ T cell receptor variable gene coding fragments, as well as its tissues, embryos, and cells. Also provided are constructs and methods for making said genetically modified non-human animal. Human T cell receptor (TCR) cloning and repertoire analysis are also included. Applications for using said animal in infectious diseases are also provided.

A non-naturally occurring test molecule for use in a cell-based screening method, wherein the molecule comprises: a molecule of interest comprising a message / address peptide; a linker sequence; and an anchor sequence which anchors the test molecule to a plasma membrane of the cell. A method of screening to determine interaction between a capture protein and a molecule of interest, the method comprising the steps of: providing the test molecule; providing a eukaryotic cell, wherein said eukaryotic cell comprises a non-endogenous capture protein; allowing the molecule of interest and the non-endogenous capture protein to interact; and determining interaction between the molecule of interest and the capture protein.